Multiple System Atrophy (MSA)
Introduction
Multiple system atrophy (MSA) was first introduced in 1969. Much remarkable progress in understanding this disorder has been developed in recent years. Together with Parkinson's disease (PD) and dementia with Lewy bodies (DLB), MSA belongs to the group of α-synuclein (αSyn), which are morphologically characterized by abnormal accumulation of fibrillary αSyn. While in patients with PD and DLB, αSyn predominantly accumulates in neurons forming Lewy bodies and Lewy neurites, in patients with MSA, it accumulates in oligodendroglia cells forming glial cytoplasmic inclusions (GCI).
Neuropathology
Although possible MSA can be diagnosed due to clinical presentations, diagnosis of definite MSA requires some neuropathological confirmations. The recognized hallmark neuropathological feature of MSA and the primary pathological event is argyrophilic filamentous GCIs. Neuropathological changes of MSA cases involve a typical lesion pattern of α-synuclein positive GCIs and neuronal loss in the striatum, substantia nigra, olivopontocerebellar pathways, and cerebellum. The duration after diagnosis is usually 6 to 10 years, with few patients surviving more than 15 years.
Clinical Presentation
Depending on their predominant motor deficits, the disease is sub-classified into a levodopa-responsive parkinsonian variant (MSA-P) associated with SND, cerebellar ataxia (MSA-C) variant with OPCA, and a combination of both forms referred to as mixed MSA. MSA-P is characterized by poorly levodopa-responsive akinesia and rigidity, postural hand tremor, impairment of postural stability, and craniocervical dystonia. The other subtype, MSA-C, is dominated by progressive gait and limb ataxia, dysarthria, and cerebellar oculomotor impairment. Age at onset, the prevalence of cardiovascular autonomic dysfunction, sleep disorders, and retinal abnormalities are similar in both phenotypes.
Fig.1 Key mechanisms underlying neurodegeneration in MSA. (Ubhi, 2011)
Genetic Risk Factors for HD
Converging evidence suggests misfolded αS to represent a key event in the pathogenic cascade leading to systemic neurodegeneration. Also, some other MSA-related factors have been studied.
- Some studies suggest that SCA1 and other forms of spinocerebellar ataxias may be associated with MSA-like presentations.
- SNCA polymorphism (encoding αS) may be associated with increased risks for MSA.
- MAPT variation has been suggested to be associated with the risk of MSA.
- Gaucher-disease-associated glucocerebrosidase (GBA) variants are associated with MSA, but whether the GBA gene L444P mutation modifies the risk for MSA deserves further studies.
- The p25alpha protein, also called tubulin polymerization promoting protein (TPPP), has been shown to colocalize with alpha-synuclein-positive CGIs and abnormally accumulate in MSA oligodendrocytes.
- Polymorphisms of several genes involved in inflammatory processes have been associated with an elevated MSA risk. These include genes coding for interleukin-1A, interleukin-1B, interleukin-8, intercellular adhesion molecule-1, and tumor necrosis factor.
Animal Models of MSA
Several neurotoxic and transgenic animal models have been developed to better understand the mechanisms underlying oligodendrocytic accumulation in MSA in the recent decade. Since the etiopathogenesis of the disease remains hitherto largely unknown, the design of MSA animal models has been based on phenotypic replication of main pathological features of the disease, which finally result in specific motor dysfunction.
Products Provided by Creative Biolabs
As a leading CRO in neuroscience, Creative Biolabs is the premier provider for MSA-related products and services. Our seasoned scientific team is pleased to offer the most satisfactory solutions to meet your specific requirements. Our specific products for MSA research include:
α-synuclein | SCA1 | SNCA | MAPT | GBA | Interleukin |
We would be pleased to provide support for any of your questions. Please ask an expert for a specific consultation on your project.
Reference
- Ubhi, K.; et al. Multiple system atrophy: a clinical and neuropathological perspective. Trends in neurosciences. 2011, 34(11), 581-590.
- iNeuMab™ Rabbit Anti-Alpha-synuclein (CBP1631) (Cat#: NAB-08-PZ079)
- iNeuMab™ Anti-Tau Antibody (NRP-0422-P2293) (Cat#: NRP-0422-P2293)
- iNeuMab™ Anti-EPHB2 Antibody (NRP-0422-P1220) (Cat#: NRP-0422-P1220)
- iNeuMab™ Anti-Alpha Synuclein BBB Shuttle Antibody (NRZP-1022-ZP4050) (Cat#: NRZP-1022-ZP4050)
- iNeuMab™ Anti-GARP Antibody (NRP-0422-P1639) (Cat#: NRP-0422-P1639)
- iNeuMab™ Rabbit Anti-LRRK2 Monoclonal Antibody (CBP1887) (Cat#: NAB-08-PZ735)
- iNeuMab™ Anti-ApoC3 BBB Shuttle Antibody (NRZP-1022-ZP3503) (Cat#: NRZP-1022-ZP3503)
- iNeuMab™ Mouse Anti-SHANK3 Monoclonal Antibody (CBP929) (Cat#: NAB-0720-Z3477)
- iNeuMab™ Anti-TNFα BBB Shuttle Antibody (NRZP-1022-ZP4105) (Cat#: NRZP-1022-ZP4105)
- Mouse Anti-Human α-Synuclein Phospho (Tyr39) (CBP3706) (Cat#: NAB201250LS)
- Mouse Retinal Ganglion Cell Line RGC-5 (Cat#: NCL2110P154)
- Mouse Glioma Cell Line GL261 (Cat#: NCL-2108P28)
- iNeu™ Human Motor Neurons (Cat#: NCL-2103-P71)
- Human Brain Vascular Adventitial Fibroblasts (Cat#: NCL-21P6-014)
- Mouse Midbrain Dopaminergic Neuron Cell MN9D (Cat#: NCL2110P059)
- Green Fluorescent BACE1 Cell Lines (Cat#: NCL2110P214)
- Rat Glioma Cell Line C6 (Cat#: NCL2110P346)
- Green Fluorescent Alpha-synuclein Cell Line (Cat#: NCL2110P209)
- Rat Immortalized Retinal Muller Cell Line rMC-1 (Cat#: NCL-2106-S93)
- Human Astrocytes (Cat#: NCC20-9PZ01)
- Beta Amyloid (1-40), Aggregation Kit (Cat#: NRZP-0323-ZP199)
- Alpha Synuclein Aggregation Kit (Cat#: NRZP-1122-ZP15)
- Human Tau Aggregation Kit (Cat#: NRP-0322-P2173)
- Amyloid beta 1-42 Kit (Cat#: NRP-0322-P2170)
- Alpha-Synuclein Aggregation Assay Kit (Cat#: NRZP-1122-ZP37)
- Beta Amyloid (1-42), Aggregation Kit (Cat#: NRZP-0323-ZP200)
- Human GFAP ELISA Kit [Colorimetric] (Cat#: NPP2011ZP383)
- Human Poly ADP ribose polymerase,PARP Assay Kit (Cat#: NRZP-1122-ZP62)
- AAV2 Full Capsids, Reference Standards (Cat#: NTC2101070CR)
- VSV-eGFP (Cat#: NTA-2011-ZP20)
- Dextran, NHS Activated (Cat#: NRZP-0722-ZP124)
- Human huntingtin-associated protein 1 (HAP1) transcript variant 2 (NM_177977) ORF clone, Myc-DDK Tagged (Cat#: NEP-0521-R0676)
- ABCA1 Antisense Oligonucleotide (NV-2106-P27) (Cat#: NV-2106-P27)
- Human huntingtin (HTT) (NM_002111) ORF clone, Myc-DDK Tagged (Cat#: NEP-0521-R0497)
- Tau Antisense Oligonucleotide (IONIS-MAPTRx) (Cat#: NV-2106-P29)
- Human apolipoprotein E (APOE) (NM_000041) ORF clone, Untagged (Cat#: NEP-0421-R0232)
- Mouse Parkinson disease (autosomal recessive, early onset) 7 (Park7) (NM_020569) clone, Untagged (Cat#: NEP-0621-R0133)
- Lenti of Human TAR DNA binding protein (TARDBP) (NM_007375) ORF clone, mGFP Tagged (Cat#: NEP-0521-R0832)
- Lenti of Mouse synuclein, alpha (Snca) transcript variant (NM_001042451) ORF clone, mGFP Tagged (Cat#: NEP-0521-R0864)
- App Rat amyloid beta (A4) precursor protein (App)(NM_019288) ORF clone, Untagged (Cat#: NEP-0421-R0053)
- Mouse SOD1 shRNA Silencing Adenovirus (Cat#: NV-2106-P14)
- NeuroBiologics™ Pig Cerebrospinal Fluid (Cat#: NRZP-0822-ZP498)
- NeuroBiologics™ Mouse Cerebrospinal Fluid (Cat#: NRZP-0822-ZP497)
- NeuroBiologics™ Rat Cerebrospinal Fluid (Cat#: NRZP-0822-ZP496)
- NeuroBiologics™ Human Cerebrospinal Fluid (Cat#: NRZP-0822-ZP491)
- NeuroBiologics™ Monkey Cerebrospinal Fluid (Cat#: NRZP-0822-ZP495)
- NeuroPro™ Anti-idursulfase BBB Shuttle Protein (Cat#: NRZP-0423-ZP497)
- NeuroPro™ Anti-ASA BBB Shuttle Protein (Cat#: NRZP-0423-ZP504)
- NeuroPro™ Anti-EPO BBB Shuttle Protein (Cat#: NRZP-0423-ZP508)
- NeuroPro™ Anti-SGSH BBB Shuttle Protein (Cat#: NRZP-0423-ZP505)
- NeuroPro™ Anti-GDNF BBB Shuttle Protein (Cat#: NRZP-0423-ZP509)
- NeuroPro™ Anti-TNFR BBB Shuttle Protein (Cat#: NRZP-0423-ZP510)
- NeuroPro™ Anti-IDUA BBB Shuttle Protein (Cat#: NRZP-0423-ZP498)
- NeuroPro™ Anti-PON1 BBB Shuttle Protein (Cat#: NRZP-0423-ZP507)
- NeuroPro™ Anti-NAGLU BBB Shuttle Protein (Cat#: NRZP-0423-ZP506)
- NeuroPro™ Anti-Erythropoietin BBB Shuttle Protein (Cat#: NRZP-0423-ZP499)